39 results about "Sildenafil" patented technology

There is provided a composition for topical application to the penis for the treatment of erectile dysfunction, the composition being free of glyceryl trinitrate (GTN), sildenafil and an acetylcholinesterase inhibitor, and comprising volatile and non-volatile solvents, the volatile solvents comprising a lower alcohol and water and the non-volatile solvents comprising a polyhydric alcohol and a glycol. Preferably, the composition does not contain any pharmaceutically active ingredients for the treatment of erectile dysfunction. Also provided is a method of determining the cooling ability of a test composition, such as the composition described above.

1. The name of the design product: packaging box (sildenafil citrate tablets langmei 2). 2. The use of the design product: the design product is used for the packaging and protection of medicines. 3. The design points of the design product: in the pattern. 4. The picture or photo that best indicates the design points: perspective view.

The application discloses a preparation method of an amido pyrazole compound and a method for preparing sildenafil by using the same. The amido pyrazole compound is shown as formula I. The compound of formula I is prepared by using 2-pentanone as an industrial chemical, and can be used for synthesizing sildenafil which is a selective inhibitor of type 5 phosphodiesterase (PDE5). The method has the advantages of easy availability of raw materials, simple operation, avoidance of nitration reaction, avoidance of safety hidden dangers caused by the nitration reaction from a technical source, and avoidance of environmental protection pressure caused by a large amount of nitration waste liquid, and is suitable for development into a green and sustainable production process of sildenafil bulk drug.

1. Name of the product in this design: Packaging Box (Sildenafil Citrate Tablets). 2. Purpose of this design: for product packaging. 3. The key design features of this product are the combination of pattern and color. 4. The image or photograph that best illustrates the design's key features: the front view. 5. The design for which protection is sought includes color.

The invention belongs to the technical field of microneedle patches, and discloses a sildenafil citrate microneedle patch preparation method, which comprises: 1, preparing a raw material solution; step 2, vacuum infusion; step 3, vacuum freeze-drying; step 4, demolding; step 5, detecting; and step 6, packaging. According to the sildenafil citrate microneedle patch, the bioavailability of the sildenafil citrate microneedle patch can be improved, the first-pass effect is effectively avoided, and a better way is provided for drug absorption and drug effect exertion; by developing a low-temperature drying process or a stabilizer formula, the drug degradation can be prevented. Meanwhile, the geometric structure of the microneedle is optimized, so that painless penetration can be ensured, deep tissues are not damaged, and the physical stability and the medicine effectiveness of the microneedle patch in the storage period can be ensured; the sildenafil citrate micro-needle patch takes effect quickly in a unique administration mode, and almost has no whole-body side effect; operation pain is avoided through the non-invasive characteristic, and the treatment comfort is improved.

The invention relates to the technical field of biomedical materials, and discloses a chitin vascular sustained release stent, which is prepared from the following raw materials in parts by weight: 50 to 70 parts of chitin; 5 to 25 parts of polyethylene glycol; 1 to 5 parts of maleic acid; 10-20 parts of calcium chloride; 0.5 to 3 parts of L-lysine; 2 to 5 parts of a sildenafil prodrug; 0.5 to 5 parts of dopamine hydrochloride; 0.5 to 5 parts of (2 amino ethyl) trimethyl ammonium chloride hydrochloride; 1 to 10 parts of sodium tripolyphosphate; 0.5 to 5 parts of nonanoic acid; and 0.1-2 parts of magnesium chloride. Chitin is matched with polyethylene glycol and calcium chloride to be dissolved out to form a swellable porous structure, residual aldehyde groups are sealed through nonanoic acid and L-lysine, and an oxidizing agent and soluble by-products are removed through washing in cooperation with sufficient deionized water, so that the scaffold is gradually dissolved in body fluid and is absorbed by tissues, and the scaffold has a good biocompatibility. Meanwhile, the stimulation of free oxidants and active aldehyde groups on cells and tissues is reduced, so that lower cytotoxicity and inflammatory response level are maintained.

1. The name of the design product: packing box (sildenafil citrate tablet). 2. The use of the design product: for packing articles. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo best indicating the design points: perspective view.

The present application relates to the technical field of health product ingredient detection, in particular to a detection method of a new type of sildenafil compound in health food, comprising the following steps: qualitative and quantitative detection by HPLC-MS / MS; the chromatographic conditions include: a chromatographic column, a C18 column; a column temperature, 40 DEG C; a mobile phase A, 0.1% formic acid aqueous solution; a mobile phase B, acetonitrile; a flow rate, 0.5 mL / min; a gradient elution program, 0~2.0 min, 10%B~95%B; 2.0~5.0 min, 95%B; 5.0~5.1 min, 95%B~5%B; 5.1~8.0 min, 5%B; a sample injection amount, 5 µL; the mass spectrometry conditions include: an ionization mode, an electrospray ionization source, a positive ion mode; an electrospray voltage, 5500 V; an ion source temperature, 550 DEG C; an atomization gas pressure, 345 kPa; an auxiliary gas pressure, 414 kPa; a curtain gas pressure, 276 kPa; a declustering voltage, 100 V; a collision energy, 45 V; a quantitative ion pair, 449 / 243; a qualitative ion pair, 449 / 259; the residence time of each ion pair, 250 ms; the new type of sildenafil compound contains a methyl piperazine group. The detection method of the present application is simple in operation, short in time consumption, high in sensitivity and good in stability.

The present disclosure relates generally to compositions and techniques for treating female sexual dysfunction (FSD), including female sexual arousal disorder (FSAD). In some embodiments, a composition, such as a cream, may be applied to the genital organ of a subject. The composition may also contain an active ingredient for the treatment of FSD and / or FSAD, such as sildenafil and / or a pharmaceutically acceptable salt thereof. In addition, certain embodiments described herein generally relate to techniques using such compositions, kits including such compositions, and the like.

1. Name of the designed product: packing box (sildenafil citrate tablet Langmei). 2. Use of the designed product: the designed product is used for packing and protecting medicine. 3. Design points of the designed product: the pattern. 4. Picture or photo best indicating the design points: perspective view.

A composition for treating astrophic vaginitis including a cream base including sildenafil citrate and oxytocin. The composition of claim 1, wherein the sildenafil citrate is in a dosage in the range of 25 mg / dose to 100 mg / dose, and oxytocin is in a dosage in the range of 40 IU / dose to 400 IU / dose. In another aspect, the composition further includes a buffering agent. In a further aspect, the buffering agent is L-arginine. In a further aspect, the buffering agent is sodium phosphate monobasic.

1. The name of the design product: packaging box (sildenafil hydrochloride tablets). 2. The use of the design product: for packaging medicines. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design points: design 1 unfolded state diagram. 5. Design 1 is designated as the basic design. 6. Other circumstances that need to be explained: The six views and the unfolded state diagram of the product are sufficient to explain the design points of the design, so the design 1 perspective and design 2 perspective are omitted.

The invention relates to nano hydrogel for treating diabetic chronic ulcer as well as a preparation method and application of the nano hydrogel. The nano hydrogel comprises a drug nano aggregate formed by sildenafil citrate and glycosylated naringin serving as a solubilizer and an antioxidant through molecular self-assembly, the hydrogel matrix is formed by crosslinking carboxymethyl chitosan and oxidized bletilla striata gum through a dynamic Schiff base reaction; wherein the drug nano aggregate is uniformly dispersed in the hydrogel matrix, and the drug nano aggregate and the hydrogel matrix jointly form the injectable and self-healing slow-release gel dressing. The method has the advantages that the hydrogel is formed through Schiff base reaction, conditions are mild, ultraviolet light or high temperature is not needed, and degradation of drugs and auxiliary materials is avoided. The gel process is rapid, and the formed gel has self-healing and injectable characteristics, can perfectly fit an ulcer wound surface with an irregular shape, and can automatically recover the structure after being damaged by shear force.

This invention discloses a sildenafil orally disintegrating film, its preparation method, and its application. The sildenafil orally disintegrating film comprises the following materials: sildenafil citrate and / or its pharmaceutically acceptable salts, methylamino methacrylate copolymers, a polymeric film-forming material, an anti-adhesive, vitamin C, a plasticizer, and a humectant. The orally disintegrating film of this invention not only effectively masks the bitter taste of sildenafil itself but also has a good taste and a short disintegration time, solving the problem of the bitter taste of traditional sildenafil citrate orally disintegrating films during administration. Furthermore, this orally disintegrating film also has good physical properties and drug stability, meeting the requirements for drug storage, transportation, and clinical use.

The invention focuses on developing final ophthalmic dosages based on Sildenafil associated with bevacizumab, known for its retino-protective properties, aimed to preserve and improve visual functions, particularly in patients with retinal degenerative disease specially for the dry form of macular degeneration

The invention relates to the technical field of biological medicine. The invention provides an application of sildenafil in preparation of a product for inhibiting adipogenic differentiation of mesenchymal stem cells. The use concentration of the sildenafil is 5-20 mg / L. The sildenafil with the concentration can remarkably inhibit the adipogenic differentiation effect of mesenchymal stem cells, and possibly inhibits the expression of adipogenic related genes by regulating a PI3K-AKT signal channel, so that bone marrow adipogenesis is reduced, the bone microstructure is improved, and osteoporosis and other diseases related to excessive adipogenic differentiation are improved. A new thought and application value are provided for reutilization of sildenafil in bone metabolism regulation and stem cell differentiation directions.

The invention provides a novel pharmaceutical composition comprising a phosphodiesterase type 5 (PDE5) inhibitor other than sildenafil and a dopamine agonist and method of use thereof for treating erectile dysfunction and / or male hypogonadism.

1. The name of the design product: packaging box (sildenafil citrate tablets). 2. The use of the design product: for packaging box. 3. The design points of the design product: in the combination of shape and pattern. 4. The picture or photo that best indicates the design points: front view.

1. The name of the design product: packaging box (sildenafil citrate tablets). 2. The use of the design product: used for the outer packaging of products. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design points: unfolded state reference drawing.

The application belongs to the technical field of microorganisms and their application, and specifically discloses a mucinophilic Akkermansia strain, a high-activity reserved inactivation method of the strain and application of the strain. The strain has a preservation number of CGMCC No. 33955, and when the strain is cultured in a mucin only carbon source culture medium for 48 hours, the OD600 value reaches 1.32 and the acetic acid yield is 18.3 mmol / L. The inactivation method uses a solution containing sulfated dextran, sucrose and epsilon-polylysine as a composite protective agent, and after the solution is mixed with the bacterial solution, the mixture is incubated at 45 DEG C to 50 DEG C for 16 min to 20 min. The inactivated strain reduces inflammation and protects lung vascular function through the "gut-lung axis", and in a MCT-induced PAH rat model, the intervention effect is close to sildenafil, and there is no increase in liver enzymes, the serum TNF-alpha and IL-6 are reduced, and the problems of large side effects and low activity reservation of existing PAH intervention are solved.

1. Name of the designed product: packing box (sildenafil citrate tablet). 2. Use of the designed product: for product packing. 3. Design points of the designed product: combination of shape and pattern. 4. Picture or photo best indicating the design points: perspective view 1.

The invention relates to a preparation method of a sildenafil intermediate, and belongs to the field of pharmaceutical chemicals. A compound 4 is obtained through a nucleophilic substitution reaction of a compound 3 and a chlorosulfonation reagent, and generation of a regional impurity M4-01 is fundamentally avoided by adopting a strategy that the position of an ethyoxyl para-position of the compound 3 is occupied in advance. According to the preparation method, the intermediate is stable, the reaction condition avoids ultralow temperature, and the energy consumption is reduced; use of chlorosulfonic acid is avoided, and the process is green and environment-friendly; the post-treatment quenching operation is simple and convenient; the total yield can reach 90% or above, and the method is more suitable for large-scale industrial production.

A composition for topical application to the penis for the treatment of erectile dysfunction is provided, wherein the composition is free of glyceryl trinitrate (GTN), sildenafil and acetylcholinesterase inhibitors, but comprises a volatile and a non-volatile solvent, the volatile solvent comprising a lower alcohol and water, the non-volatile solvent comprising a polyol and a glycol. Preferably, the composition is free of any pharmaceutically active ingredient for the treatment of erectile dysfunction. A method of determining the cooling capacity of a test composition, e.g. the above-mentioned composition, is also provided.

There is provided a composition for topical application to the penis to treat erectile dysfunction wherein the composition is free of glyceryl trinitrate (GTN), sildenafil and an acetylcholin esterase inhibitor, but comprises volatile and non-volatile solvents, the volatile solvent comprising a lower alcohol and water, the non-volatile solvent comprising a polyol and a diol. Preferably, the composition is free of any pharmaceutically active ingredient for the treatment of erectile dysfunction. Also provided is a method of determining the cooling capacity of a test composition (e.g., the above composition).

1. Name of the product in this design: Packaging Box (Sildenafil Citrate Tablets 7). 2. Purpose of this design: This design is used for the packaging and protection of pharmaceuticals. 3. The key design feature of this product is its pattern. 4. The image or photograph that best illustrates the design's key points: a 3D model.

A composition for treating atrophic vaginitis including sildenafil citrate USP (C22H30N6O4SC6H8O7), oxytocin USP (C43H66N12O12S2), boric acid, Chlorobutanol, Sodium phosphate monobasic and L arginine or L arginine HCI as a buffering system formulated in a suitable, non stainable and non leaky vaginal cream base. A method of treating atrophic vaginitis comprising topically administering the composition to a patient in need thereof.

The invention provides an aldenafil citrate orally disintegrating tablet as well as a preparation method and application thereof. The aldenafil citrate orally disintegrating tablet comprises the following components: a pharmaceutical active component, an auxiliary carrier, a disintegrating agent, a filling agent, a flavoring agent, an adhesive and a lubricant, the active pharmaceutical ingredient comprises aldenafil citrate and / or a pharmaceutically acceptable salt thereof; the auxiliary carrier comprises any one or a combination of at least two of a water-soluble vitamin E derivative, an organic acid or an organic acid salt. The adenafil citrate orally disintegrating tablet provided by the invention has better taste, is convenient to take, does not need water, can be quickly disintegrated in the oral cavity, the disintegration time limit does not exceed 60 seconds, the maximum plasma concentration time does not exceed 1 hour, and the requirement that the adenafil citrate needs to take effect quickly under specific conditions is met.

The application discloses a new use of sildenafil and its salts in combination with ibuprofen. Through pharmacodynamics and toxicology experiments, the application first proposes and verifies that the combination of sildenafil and its salts (sildenafil citrate) and ibuprofen has a significant synergistic effect in treating inflammatory pain, and can effectively reduce the renal toxicity induced by long-term administration of ibuprofen. The application solves the problem that long-term or large-dose use of ibuprofen can induce significant renal toxicity, which seriously limits the long-term, standard and sufficient clinical application of ibuprofen. The composition provided by the application can enhance the analgesic effect of ibuprofen and reduce the renal toxicity of ibuprofen, and has important clinical conversion value and practical application prospect.

The invention discloses a sildenafil citrate orally disintegrating tablet and a preparation method thereof, and the sildenafil citrate orally disintegrating tablet comprises the following components in parts by weight: 68-75 parts of sildenafil citrate, 300-320 parts of mannitol, 15-19 parts of polyvinylpolypyrrolidone, 55-75 parts of polyvinyl acetate aqueous dispersion, 20-35 parts of a disintegrating agent, 20-35 parts of a filler, 3-6 parts of a flow aid and 2-5 parts of a coloring agent. 5-20 parts of a flavoring agent, 5-20 parts of an aromatic and 5-20 parts of a lubricant. According to the product disclosed by the invention, the dissolution rate is improved, the bitterness of the preparation is covered, the taste and smell of the product are improved, the stability of the product and the compliance of a patient are improved, and the production cost is reduced.

The invention belongs to the technical field of microorganisms and application thereof, and particularly discloses Ackermania muciniphila as well as a high-activity retention and inactivation method and application thereof. The preservation number of the strain is CGMCC (China General Microbiological Culture Collection Center) No.33955, and when the strain is cultured in a mucoprotein unique carbon source culture medium for 48 hours, the OD600 value reaches 1.32, and the yield of acetic acid is 18.3 mmol / L. According to the inactivation method, a solution containing sulfated dextran, cane sugar and epsilon-polylysine is used as a composite protective agent and is mixed with a bacterial solution, and then the temperature of 45-50 DEG C is kept for 16-20 min. The inactivated strain reduces inflammation and protects the pulmonary vascular function through an intestine-lung axis, in an MCT-induced PAH rat model, the curative effect after intervention is close to that of sildenafil, liver enzyme rise and serum TNF-alpha and IL-6 reduction do not exist, and the problems that existing PAH intervention is large in side effect and low in activity retention are solved.